Table 2.
Comparison of EGFR dataset to all patients in the database
| Characteristic | EGFR data | No EGFR data | |
|---|---|---|---|
| Age | Number tested | 2552 | 52,293 |
| Median Age | 61 | 62 | |
| < 50 years | 27% | 25% | |
| ≥ 50 years | 73% | 75% | |
| Tumor size | Number tested | 2420 | 50,229 |
| ≤ 2 cm | 51% | 51% | |
| 2 – 5 cm | 42% | 42% | |
| > 5 cm | 7% | 7% | |
| Nodal status | Number tested | 2263 | 48,376 |
| 0 | 62% | 60% | |
| 1–3 | 23% | 23% | |
| > 3 | 15% | 18% | |
| Tumor ploidy | Number tested | 2515 | 4366 |
| % Diploid | 50% | 47% | |
| % Aneuploid | 50% | 53% | |
| S-phase | Number tested | 2251 | 3912 |
| Low | 52% | 52% | |
| Intermediate | 20% | 19% | |
| High | 28% | 28% | |
| ER | Number tested | 2567 | 52,298 |
| Positive | 83% | 82% | |
| Negative | 17% | 18% | |
| PR | Number tested | 2567 | 52,298 |
| Positive | 58% | 60% | |
| Negative | 42% | 40% | |
| HER2 | Number tested | 2200 | 56 |
| Positive | 18% | 7% | |
| Negative | 82% | 93% | |
| Hormone receptor groups | Number tested | 2567 | 52,298 |
| ER+/PR+ | 56% | 57% | |
| ER+/PR− | 27% | 24% | |
| ER−/PR+ | 2% | 3% | |
| ER−/PR− | 14% | 15% |